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Objective To provide evidence of the existence of membrane
progesterone receptor alpha (mPRa) on regulatory T cells (Treg)
in peripheral blood during pregnancy, postulating a possible
explanation for the effect of progesterone on preterm birth.
Design Cross-sectional study.
Setting Tertiary Obstetric Department in a University Hospital.
Population Healthy pregnant women.
Methods Treg cells from peripheral blood samples were studied
by flow cytometry using multiple monoclonal antibody
expression.
Main outcome measures Evaluate the number and percentage of
CD4+CD25highCD127low, the number and percentage of Treg cells
among the total CD4+ T cells, and the percentage and mean
fluorescence intensity (MFI) of mPRa in that population, using
several gating strategies.
Results 43 peripheral blood samples were collected from healthy
women during pregnancy, whose median gestational age was
28.7  7.1 (16–40) weeks. The percentage of CD4+ in the total
lymphocytes was 43% (32–51) and the percentage of
CD4+CD25highCD127low was 4.8% (1.6–5.9), with only 45% (16–
72) of those cells expressing the intracellular marker FoxP3 (Treg
cell pool). We confirmed the existence of mPRa in that specific
population because 8.0% (2.02–33) of the Treg cells were marked
with the specific monoclonal antibody, with an mPRa+ MFI of
719 (590–1471).
Conclusions This research shows that Treg cells express mPRa
during pregnancy, which might play an important role in immune
modulation by progesterone.
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Introduction
It is commonly accepted that the act of giving birth is the
final step in a pro-inflammatory signalling cascade. Conse-
quently, the inflammatory process plays a pivotal role in
the triggering of human labour both in term and in pre-
term birth (PTB).1
Maternal acceptance of the fetus during pregnancy
results from T-cell tolerance rather than immunosuppres-
sion. However, there is strong evidence that maternal T
cells are not exposed to fetal alloantigens and that changes
in the production of progesterone play a major role in
modulating local immunosuppression.2
The abundance or modulation of systemic regulatory T
cells (Treg) could be involved in pregnancy complications.3,4
However, it is not known whether the Treg suppressive
mechanism is specific to PTB or if it is also involved in
spontaneous normal term birth.5 Progesterone has a major
role in pregnancy maintenance and its secretion has been
demonstrated in the amnion, chorion and decidua in
humans.6,7
In the 1st trimester, progesterone is critical to pregnancy
preservation until the placenta takes over this function. In
later pregnancy, however, its function is less clear.8
Although progesterone levels in the maternal circulation do
not change significantly in the weeks or days preceding
labour, the onset of labour is associated with a functional
withdrawal of progesterone activity.8,9
There are several unanswered questions surrounding the
role of progesterone in human pregnancy. Of these, the
questions of what molecular mechanisms support proges-
terone action during pregnancy and what molecular
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changes turn off progesterone signalling and allow parturi-
tion, are the most intriguing.10 In the quest for a novel
agent in PTB treatment, progesterone emerges as a good
candidate due to its immunomodulatory action.11 Although
the exact mechanism of its immunomodulatory role is still
unknown, reports demonstrate its rapid effects on human
T cells.2,12
The extranuclear activity of progestins was identified to
be mediated by an alternative membrane-localised proges-
terone receptor (mPR), which may be responsible for the
rapid cell activation prompted by progesterone11,13 and
progesterone interaction with the immune system.14
The function of one of these receptors, mPRa, has been
investigated15 but its expression on specific subsets of
immune cells has hardly been demonstrated.12,16
It is thus tempting to infer that mPRa is the mechanism
by which progesterone regulates Treg cells, explaining pro-
gesterone actions during pregnancy and PTB. The aim of
this investigation is to ascertain whether mPRa is present
on Treg cells in peripheral blood during pregnancy.
Methods
We undertook a cross-sectional study of healthy women
attending normal prenatal appointments at our Obstetrics
Unit between December 2013 and May 2014. Exclusion cri-
teria consisted of multiple gestation, pre-existing disease,
preterm rupture of membranes, chorioamnionitis, placenta
praevia, placental abruption, clinical signs of infection
(maternal temperature ≥37.5°C, white blood cells ≥15 000
cells/mm3 in maternal blood) or use of hormone therapies
within 3 months before enrolment.
Gestational age was assessed by date of last menstrual
period or by ultrasound performed in the first trimester.
The investigation was approved by the Ethical Commit-
tees of Coimbra University and Coimbra University Hospi-
tal and informed consent was obtained from each
participant.
Specimen collection
Peripheral venous blood samples were obtained and col-
lected in lithium heparin tubes. Samples were kept in a
cool environment until being processed within 1 hour of
collection.
Flow cytometry staining
In brief, 100 ml of whole blood containing 0.5–1 9 106
white blood cells was placed in a clean test tube and stained
to localise the mPRa receptor on the cell surface, using the
N-terminal mPRa antibody described by Thomas et al.17
Cells were first incubated in a blocking solution [0.5%
bovine serum albumin {BSA}], in phosphate-buffered saline
(PBS) for 30 minutes to 1 hour and then incubated with
the mPRa antibody (Santa Cruz Biotechnology, Inc., Dallas,
TX, USA) at room temperature for a further 30 minutes to
1 hour. Cells were washed with PBS 0.5% BSA and incu-
bated for 30 minutes with Cruz Fluor 488 goat anti-rabbit
IgG secondary antibody (Santa Cruz Biotechnology, Inc.) at
room temperature in the dark. Cells were washed with the
blocking solution, and the surface was stained with PB con-
jugated anti-CD4, PE-Cy7 conjugated anti-CD25, and
PerCP-Cy 5.5 conjugated anti-CD127.
Subsequently, intracellular staining for detection of
FoxP3 was performed using AF647 labelled anti-human
FoxP3 (Biolegend, San Diego, CA, USA) and the staining
set (eBioscience, San Diego, CA, USA) according to the
manufacturer’s instructions. Flow cytometry data were
acquired on a FACS Canto II instrument (BD Biosciences,
San Jose, CA, USA) equipped with three lasers to allow
multicolour detection with different fluorophors, using FACS
DIVA software (BD Biosciences).
Lymphocyte populations were selected according to the
forward angle (FSC-A) and side angle (FSC-H) scattering
signal, and at least 50 000 gated lymphocyte cells were
detected for each sample. Dead cells were excluded by for-
ward and side scatter characteristics and an FSC-A versus
FSC-H dot plot was used to discriminate doublets, detect-
ing disparity between cell size versus cell signal.
Isotype control antibodies were used to help assess the
level of background staining, as well as samples without
staining and single stain, for each antibody.
Treg analysis and mPRa expression
Gating strategies were employed to evaluate the percentage
of CD4+CD25highCD127low cells, the percentage of Treg
cells in total CD4+ T cells, and the percentage and mean
fluorescence intensity (MFI) of mPRa in that population.
Our gating strategy for identifying the Treg population
was based on a total lymphocyte gate based on a FSC/Side
light scatter (SSC) dot plot followed by doublet discrimina-
tion with an FSC-A versus FSC-H dot plot. Accordingly,
CD4-positive cells were gated over SSC characteristics;
depending on CD25 and CD127 expression, CD4+ cells
were gated based on the expression of CD25high and
CD127low markers, and the CD4+CD25highCD127low popu-
lation was detected. As the literature varies as to the mark-
ers for the exact phenotype for a Treg cell population, we
moved on to the CD4+CD25highCD127low population, and
also searched for FoxP3+ cells. In the CD4+CD25high
CD127lowFoxP3+ (regulatory T-cell population), the mPRa+
subset was identified and characterised by percentage and
mean fluorescence intensity (MFI).
The statistical analysis was based on at least 15 000–
20 000 gated CD4+ cells. FLOWJO software (Tree Star Data
Analysis Software, Ashland, OR, USA) was used for the
flow cytometry analysis.
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Real time PCR and Western blot analysis
For mPRa assessment by RT-PCR and Western blot, blood
samples were submitted to Ficoll-hypaque density gradient
centrifugation to obtain peripheral blood mononuclear cells
(PBMCs). PBMCs were then collected under optimal con-
ditions to ensure high purity samples. Part of the PBMCs
were lysed in RNeasy RLT lysing buffer (Qiagen, Austin,
TX, USA) and frozen at 80°C until RNA extraction. The
rest of the cells were treated with RIPA buffer and com-
pleted with protease inhibitors, which enables rapid and
efficient cell lysis and solubilisation of proteins until subse-
quent Western blot assays. Both techniques were performed
based on protocols previously described by Ndiaye et al.,18
Thomas et al.17 and Dosiou et al.16 RT-PCR results were
analysed in a Light Cycler 480 (Roche Instruments).
Statistical analysis
Data were analysed by IBM SPSS 21 Statistics software
(IBM Corporation, Armonk, NY, USA) and data are
expressed as mean  standard deviation (SD) or median
and interquartile range (IQR) values, as appropriate for the
type of distribution.
Using the nonparametric Mann–Whitney U-test, statisti-
cal comparison were made between groups of the total
number and percentages of CD4+CD25highCD127low of
CD4+ T cells, the total number and percentages of the Treg
cell subset within the total CD4+CD25highCD127low popula-
tion, and the total number and percentages of mPRa+ Treg
cells, and the MFI between the different women’s charac-
teristics (parity and gestational age) was determined. Statis-
tical significance was considered for a P value <0.05. There
were no missing data in our population sample.
Results
A total of 43 peripheral venous blood samples were
extracted from healthy pregnant women with a median ges-
tational age of 28.7  7.1 (16–40) weeks, divided between
2nd trimester (42%; n = 18) and 3rd trimester (58%;
n = 25). Clinical data of the population are shown in
Table 1.
First, CD4+ T cells were gated and analysed for the
expression of CD25 and CD127; subsequently, the number
and percentage of CD4+ CD25high CD127low cells were esti-
mated for all participants. Afterwards, Treg cells were char-
acterised by the expression of FoxP3 and mPRa to estimate
both the percentage and absolute number of Treg cells and
the mPRa+ expression on those Treg cells. The MFI of
mPRa+ on Treg cells was estimated for all participants.
Figure 1 (A,B in the main article, Figure S1a–d) shows
our flow cytometric gating strategy for the
CD4+CD25highCD127lowFoxP3+ population (regulatory T-
cell population) in peripheral blood.
Table 1. Clinical data
Variable Value
Age (Years)
Mean  SD (min–max) 30  4.8 (21–37)
Gestational age (weeks)
Mean  SD (min–max) 28.7  7.1 (16–40)
n = 43
Nullipara (n, proportion) 29 (67%)
2nd Trimester (n, proportion) 18 (42%)
3rd Trimester (n, proportion) 17 (39%)
Delivery (n, proportion) 8 (19%)
A
B
Figure 1. Flow cytometric gating strategy for
CD4+CD25highCD127lowFoxP3+ Treg analysis in peripheral blood.
Peripheral blood lymphocytes were stained with FITC-labeled anti-mPRa,
APC-labelled anti-FoxP3, PE-Cy7-labeled anti-CD25, PerCP-Cy 5.5-
labeled anti-CD127 and PE-labelled anti-human CD4 antibodies. A, FITC
anti-mPRa histogram: percentage of mPRa+ subset within the total
CD4+CD25highCD127lowFoxP3+Treg cell pool. B, Isotype control for
mPRa.
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Table 2 shows the absolute number and percentage of
the different populations studied, in the normal course of
pregnancy.
As the results show, the percentage of CD4+ in the total
lymphocytes was 43% (32–51) and the percentage of
CD4+CD25highCD127low was 4.8% (1.6–5.9), with only
45% (16–72) of those cells expressing the intracellular mar-
ker FoxP3 (Treg cell pool).
We were able to verify the expression of mPRa in that
specific population, as 8.0% (2.0–33) of those Treg cells
were positive for this marker, with an mPRa+ MFI of 719
(590–1471).
To ascertain whether the number or percentage of CD4+
cells, CD4+ CD25high CD127low, Treg cells and mPRa+ Treg
cells varied with different clinical characteristics, a sub-
group analysis was done, as shown in Supporting Informa-
tion Table S1. The clinical characteristics analysed
compared with others were as follows: parity (nullipara if it
was the first pregnancy); 2nd trimester (14–27 weeks); 3rd
trimester (≥28 weeks); delivery date.
The percentage and absolute number of
CD4+CD25highCD127low was elevated in women in the 3rd
trimester or at delivery date (P = 0.001), with the highest
levels at delivery date (P = 0.04 and P = 0.007, respec-
tively).
The percentage and absolute number of Treg cells were
higher in women in the 3rd trimester, with the strongest
difference shown in the percentage of Treg cells (P = 0.02).
Finally, the percentage of mPRa+ Treg cells was higher
in the nulliparas (P = 0.026) and there was an increase in
the absolute number of mPRa+ Treg cells from the 2nd to
the 3rd trimester of pregnancy, although this was not
statistically significant (0.25 versus 1.22, P = 0.08, respec-
tively). No other comparisons between groups had statisti-
cal significance, although a trend towards a higher number
of CD4+ cells could be perceived in the date of delivery
(P = 0.058).
Western blot experiments designed to examine mPRa
protein expression showed the presence of a protein about
40 kD in size in our PBMC samples. Representative results
of two independent experiments are shown in Figure 2.
Moreover, expression of mPRa mRNAs was detected by
RT-PCR using mPRa-specific primers.
Discussion
Progesterone has been known to play an important role
in the reproductive tract for the initiation and continua-
tion of pregnancy, with good results in the prevention of
spontaneous abortion and recently in preterm labour.
Nonetheless, progesterone-mediated responses are complex
because they are mediated by multiple types of recep-
tors.19
Undoubtedly this steroid is able to prevent the maternal
immune system from activating effector T-cells capable of
attacking fetal cells, resulting in a T-cell tolerance during
pregnancy.2 Recent data suggest that progesterone may be
important in maintaining uterine quiescence in the latter
half of pregnancy by limiting the production of stimulatory
prostaglandins and inhibiting the expression of contrac-
tion-associated protein genes within the endometrium.8
However, the exact route by which this is accomplished is
still being researched.
Regulatory T cells were shown to expand during human
pregnancy, with functional studies finding that they create
a tolerant microenvironment through regulation of
immune cell responses at the fetal–maternal interface.20Table 2. Absolute number and percentage of the different
populations studied
n = 43 CD4+ (total
lymphocytes)
CD4+
CD25high
CD127low
(in CD4+ T
lymphocytes)
Treg cells
(in CD4+
CD25high
CD127low)
CD4+
CD25high
CD127low
FoxP3+
mPRa+
% Cells
Median 43 4.8 45 8.0
IQR (32–51) (1.6–5.9) (16–72) (2.0–33)
Absolute number*
Median 959.9 42.91 11.5 0.98
IQR (302.1–1517.4) (3.23–86.2) (1.07–36.5) (0.08–2.55)
MFI
Median – – – 719
IQR (590–1471)
IQR, interquartile range; MFI, mean fluorescence intensity.
*number cells/ll blood.
Figure 2. Representative results of Western blot analysis. Western blot
analysis of mPRa expression in peripheral blood mononuclear cells
(PBMCs): 20 lg/protein/lane; mPRa antibody concentration (1 : 2000).
Lane 1 – molecular weight marker; kD. Lanes 2 and 3 – mPRa in
PBMCs.
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Since 1980, some groups have tried to identify expres-
sion of progesterone receptors during pregnancy, although
with contradictory results.21,22 Nevertheless, the gathering
of scientific effort has enabled not only the presence of
lymphocytic progesterone receptors23 to be verified, but
also validation of the existence of progesterone-induced
blocking factor and its role in pregnancy.24 Recently, some
authors have attempted to demonstrate that the actions of
progesterone on T lymphocytes are mediated by one or
more putative membrane receptors, but all experiments
were done in non-pregnant animal models.18 Moreover,
although receptors for oestrogens have been confirmed in
Treg cells,25 to the best of our knowledge progesterone
receptors have not been studied in this subset of human
cells.
Main findings
This research postulates a primordial role for mPRa in the
intertwining between Treg cells and progesterone in human
pregnancy.
In our work, we have shown the existence of mPRa in
the Treg cell pool, with 8.0% of Treg cells being mPRa+,
with an MFI of 719.
Some authors have indicated a significant decrease in
CD4+ T cells within the total leucocyte pool in spontane-
ous labour, which could indicate that a strong immune
stimulation and subsequent apoptosis of the activated
CD4+ T cells may occur during labour.5 When comparing
our results with those published in the literature, this pop-
ulation remained almost unchanged throughout the whole
pregnancy, with a slight increase on delivery day, which
contrasts with published literature.
CD4+CD25highCD127low isolated Treg cells appear to be
the best Treg population achieved regarding purity, func-
tion, stability and in vitro expansion capacity, promising
isolation of pure Treg populations with high suppressive
activity.26 Our results were similar to published ones, with
CD4+CD25highCD127low cells making up 4.8% (1.6–5.9) of
the CD4+ T-cell population.
However, the most widely accepted phenotype for Treg
cells is the co-expression of CD4, CD25 [a-chain of the
interleukin (IL)-2 receptor] and FoxP3.27 We therefore
assumed that the CD4+CD25highCD127low FoxP3+ is the
phenotype of the Treg cell pool.
FoxP3 is regarded as a lineage molecule for Treg cells
and it is an intracellular marker. Consequently, it is very
susceptible to degradation within a short space of time,
and it is difficult to detetct and not really usable in large
sample series. Moreover, FoxP3+ T cells are phenotypically
and functionally heterogeneous and involve both suppres-
sive and non-suppressive T cells.27
Furthermore, CD127 was for a long period seen as an
efficient tool to determine the phenotype and functional
activity of Treg cells. Yet, there has been increasing contro-
versy in comparisons with CD4+CD25highFoxP3+ cells, par-
ticularly in the context of chronic infections.27 However,
no attention was given to it in the context of pregnancy.
As such, it is currently accepted that CD127 expression
inversely correlates with FoxP3 expression and suppressive
activity of Treg cells .27
The data reported in the literature concerning the effect
of pregnancy-specific hormones on FoxP3 expression by
Treg cells are very contradictory.5 The withdrawal of hor-
mones at the end of pregnancy may affect FoxP3 expres-
sion by Treg cells, which was shown to be enhanced by
progesterone in human studies.3 Other authors postulate
that progesterone, whose maximum levels are seen at the
end of pregnancy, has the capacity to reduce FoxP3 expres-
sion by Treg cells in vitro.25 Moreover, recent data indicate
a significant decrease of Treg cells expressing FoxP3 in the
3rd trimester and women in labour at term.5
We therefore also determined FoxP3 expression in our
research, making some comparisons feasible. Within
CD4+CD25highCD127low cells, only 45% were Treg cells,
corroborating the idea that Tregs in pregnant women have
a reduced expression of FoxP3.25
Strengths
The strengths of our research lie in the fact that this is the
first report on humans regarding the existence of mPRa in
Treg cells, which is of utmost importance as it opens up a
promising field in immunology and may help to explain
more exactly the effects of progesterone on PTB, thereby
allowing its more rational, widespread and effective use.
Moreover, as all methods are thoroughly described, the
results are open to reproducibility studies by research groups.
Limitations
Nevertheless, there are limitations in our study that need
to be taken into account. The different antibody panel cho-
sen to characterise our populations is controversial (as dis-
cussed previously) and the small number of samples means
our results should be considered with caution.
Interpretation
Controversies still persist that could not be solved by our
results. The variation of the number of Treg cells during
the three trimesters of human pregnancy is still under
debate, with some authors reporting a rise in the 1st tri-
mester with a peak in the 2nd trimester, and others report-
ing a reduction in the 2nd trimester.28 In our study, the
percentage and absolute number of CD4+CD25high
CD127low cells was highest at delivery, suggesting the likely
importance of activation of this population in the recrudes-
cence of the inflammatory phenomenon nowadays believed
to be labour. The results for Treg cells, with the highest
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levels in the 3rd trimester, make this hypothesis even more
reasonable.
Finally, the higher percentage of mPRa+Treg cells in the
nulliparas could be explained by the different physiological
characteristics that differentiate circulating immune cells in
pregnant women who have had a previous delivery.
Conclusions
We demonstrated the existence of mPRa in the circulating
Treg cell pool. More information regarding its existence in
the maternal–fetal interface (decidua) is necessary.
Further investigation should determine the functionality
of this receptor and the mechanisms by which Treg cells
modulate fetal protection and labour. Membrane progester-
one receptor a might emerge as an instrument by which
progesterone regulates Treg cells, allowing a rational rec-
ommendation for progesterone usage in PTB.
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